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a  b  s  t  r  a  c  t
Eosinophilic granulomatosis with polyangiitis is a rare primary vasculitic disease character-
ized  by hypereosinophilia, late onset asthma and extravascular eosinophil granulomas. We
report a case presented initially with acute myocardial infarction which later only proceed
with asthma, skin manifestations and peripheral neuropathy. Laboratory parameters
showed hypereosinohpilia with negative perinuclear pattern of antineutrophil cytoplasmic
autoantibodies (p-ANCA). Skin biopsy showed leucocytoclastic vasculitis with eosinophilic
inﬁltration while coronary angiography was normal. The patient’s symptoms improved with
IV  methylprednisolone, pulse cyclophosphamide and azathioprine.
© 2014 Elsevier Editora Ltda. All rights reserved.
Infarto  agudo  do  miocárdio  como  apresentac¸ão inicial  de  granulomatose
eosinofílica  com  poliangiite  (anteriormente,  síndrome  de  Churg  Strauss)
alavras-chave:
índrome de Churg Strauss
r  e  s  u  m  o
A granulomatose eosinofílica com poliangiite é uma vasculite primária rara, caracterizada




Relatamos um caso apresentado inicialmente com infarto do miocárdio e que, ulteri-
ormente, teve prosseguimento apenas com asma, manifestac¸ões cutâneas e neuropatia
periférica. Os parâmetros laboratoriais revelaram hipereosinoﬁlia com um padrão peri-
autoanticorpos citoplásmicos antineutróﬁlos (p-ANCA). A biópsia desma nuclear negativo de 
nfarto do miocárdio pele demonstrou vasculite leucocitoclástica com inﬁltrac¸ão eosinofílica, diante de uma
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angiograﬁa coronária normal. Os sintomas do paciente melhoraram com metilprednisolona
IV,  pulsoterapia com ciclofosfamida e azatioprina.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
Figure 1 – Skin biopsy of this patient which shows
lymphocytic and eosinophilic inﬁltrations consistent withIntroduction
Eosinophilic granulomatosis with polyangitis (EGPA), or previ-
ously better known as Churg Strauss Syndrome (CSS), is a rare
disorder with an annual incidence of 2.7 cases per million.1 It
is characterized by hypereosinophilia, late onset asthma and
extravascular eosinophil granulomas. This was ﬁrst described
by Churg and Strass in 1951.2 EGPA is variable in its manifesta-
tions, which may range from skin lesions, asthma, non-erosive
arthritis to life threatening conditions, such as cardiac dis-
ease, severe gastrointestinal and peripheral nervous system
involvement. Cardiac involvement is a leading cause of mor-
tality, accounting for 48% of deaths in EGPA.3
The 1990 American College of Rheumatology (ACR) classiﬁ-
cation criteria for EGPA required the presence of four or more
of the following six criteria for making the diagnosis: asthma,
eosinophilia (>10% of leukocytes by differential cell count),
mononeuritis multiplex or polyneuropathy, pulmonary inﬁl-
trates (may  be transient, paranasal sinusitis and histological
proof of vasculitis with extravascular eosinophils).4 The
recently published 2012 Revised International Chapel Hill
Consensus Conference (CHCC) Nomenclature of Vasculitides
stated EGPA as an antineutrophil cytoplasmic antibodies
(ANCA) associated vasculitides with eosinophil-rich and
necrotizing granulomatous inﬂammation often involving the
respiratory tract, and necrotizing vasculitis predominantly
affecting small to medium vessels, and associated with
asthma and eosinophilia.5
We  report a 50-year-old man  presented with inferior
myocardial infarction who  later developed skin manifes-
tations, exacerbation of bronchial asthma and disabling
peripheral neuropathy.
Case  report
A 50-year-old male was presented at our emergency depart-
ment with severe chest pain and shortness of breath for 2 days.
His past medical history revealed hypercholesterolemia with
no previous hospitalizations. The 12-lead electrocardiogram
(ECG) showed a sinus rhythm and ST-segment elevation in
the inferior leads. Echocardiography revealed a good left ven-
tricular systolic function with ejection fraction of 78% with
no regional wall motion abnormality. Laboratory assessment
showed raised CKMB 148 U/L (normal < 25 U/L) and LDH 2,047
U/L (normal 200-480 U/L). Due to late presentation, he was
not thrombolyzed. He was prepared for percutaneous cardiac
intervention (PCI), but he refused. He was discharged with
medications for coronary artery disease.
Two weeks later, he developed multiple painful nodular
lesions over his soles and hands associated with intermittent
fever. Further questioning revealed that he had been sufferingleukocytoclastic vasculitis.
from dry cough for 1 year for which he did not seek any treat-
ment. There was no allergic rhinitis or any symptoms that
might suggest asthma. However, he still experienced chest
discomfort since discharged 2 weeks ago.
Chest radiograph was normal. Repeated echocardiographs
showed global hypokinesia with poor left ventricular sys-
tolic function of 35%. Laboratory analyses showed an increase
white blood cell count (14,900/L) with predominance of
eosinophils (33%), LDH 863 U/L, raised erythrocyte sedimen-
tation rate (52 mm/h), CRP (125 U/L) and positive rheumatoid
factor. Immunological markers, such as antinuclear anti-
body, perinuclear and classic ANCA, extractable nuclear
antigen were all negative. A skin biopsy was performed and
showed dense neutrophilic and lymphocytic inﬁltrations with
eosinophilic vasculitic changes (Fig. 1). He only fulﬁlled 2 out
of the 6 of the ACR classiﬁcation criteria with no history of
asthma or sinusits. However, he was given prednisolone 60 mg
(1 mg/kg), and his skin lesions improved. This time he agreed
on undergoing coronary angiography, which showed no evi-
dence of atheroma on coronary luminogram.
Four months later, he presented with exacerbation of
bronchial asthma with nocturnal cough. There were no new
skin lesions or chest pain. His symptoms improved with neb-
ulizers and a short course of prednisolone 30 mg  (0.5 mg/kg)
for 5 days.
During the follow-up, 6 months later, his complaint of Ray-
naud’s phenomenon and numbness over both his lower limbs
with more  prominent over the right foot. This was proceeded
with right foot dorsiﬂexion weakness. The physical exam-
ination revealed right foot drop, vasculitic lesions over the
palms and a nodule with necrotizing surface over the right
hand. Laboratory ﬁndings showed raised white cell counts 22.2
with eosionophils (78.8%), ESR 32 mm/h  and CRP 64 U/L. Elec-
tromyography and nerve conduction studies were consistent
with sensorimotor polyneuropathy.
He was given IV methylprednisolone 500 mg  daily for three
days followed by 60 mg  of oral prednisolone (1 mg/kg) and
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mlodipine 5 mg  daily. After the completion of IV methyl-
rednisolone, monthly intravenous cyclophosphamide was
dministered for 6 months. The patient responded well to
he treatment, with improvement of the symptoms After the
ompletion of the pulse cyclophosphamide, he was added on
zathioprine 25 mg  daily.
Throughout the 8 years follow-up, there was no relapse
fter initiation of the immunosuppressive treatments. How-
ver, the patient still experience some residual neurological
eﬁcit of the right foot. Otherwise, the laboratory parameters
nd echocardiography were all normal.
iscussion
GPA is a multisystem vasculitic disorder which involve
edium to small sized muscular arteries and veins. It
s typically manifested in 3 consecutive phases. The pro-
romal phase consists of allergic manifestations. The
econd phase involves tissue eosinophilia inﬁltration and
lood eosinophilia. This is followed by vasculitic sys-
emic manifestations.6 However, this patient had a different
equence in which acute myocardial infarction was the initial
resentation and asthmatic symptoms only appeared later.
EGPA may affect the myocardium, valves, coronary arteries
nd pericardium. This will lead to structural and func-
ional impairment.7 Eosinophils inﬁltrate the myocardium
nd release toxic inﬂammatory mediators which lead to
rrhythmias and systolic dysfunction.8 Cardiac involvement
s the major cause of mortality in EGPA with poor outcomes,
ut it is fully reversible as occurred in this patient.9 However,
oth 1990 ACR classiﬁcation criteria and the new revised CHCC
omenclature do not emphasize on cardiac symptoms.
Peripheral nerve involvement is the most frequent vas-
ulitic manifestation of EGPA.10 Most patients responded
ell with immunosuppressive therapy, however some resid-
al symptoms might persist as in this case.11 Other organs
nvolvement includes cutaneous lesions, lungs (asthma, nasal
olyps), kidney and gastrointestinal involvement.
Laboratory parameters were non-speciﬁc, which included
aised ESR, CRP and eosionophil counts.
Anti-MPO perinuclear ANCA (p-ANCA) can be found in
nly 30%-40% of patients with EGPA.12 Most patients with
ositive ANCA had glomerulonephritis, peripheral neurop-
thy and vasculitis in biopsy.13 It was negative in our patient.
ndeed, few literatures had reported that EGPA with heart
nvolvement are mainly ANCA negative.13,14 Persistent hyper-
osinophilia alone does not exclude other diagnosis such
s hypereosinophilic syndromes. However, the presences of
ther clinical manifestations help to reach the diagnosis.
The ﬁve-factor score was developed by the French Vasculi-
is Study Group to predict the risk of death in EGPA. This
ncludes, reduced renal function (creatinine > 1.58 mg/dL or
40 moL/L), proteinuria (> 1 g/24 h), gastrointestinal hemor-
hage, infarction or pancreatitis, involvement of the central
ervous system and cardiomyopathy. Presence of any one of
hese have 5-year mortality of 26%, while 2 or more  with 46%
ortality.15
Currently, there is no established protocol for treatment
f EGPA. The type of treatment mainly based on the severity 4;5 4(5):393–396 395
of the disease. Minor manifestations, such as asthma or
cutaneous manifestations can be treated with corticosteroids
alone. Life threatening multisystem involvement (acute coro-
nary syndrome, severe peripheral polyneuropathy or severe
gastrointestinal involvement) required combination therapy
of glucocorticoids and cyclophosphamide. In this patient,
he was given 3 consecutive days of intravenous methyl-
prednisolone (500 mg/m2) followed by monthly pulse of IV
cyclophosphamide (750 mg/m2) for 6 months.
There was a delay in reaching the diagnosis in this patient
as asthmatic symptoms only become apparent after 5 months
of the initial presentations. It took approximately 10 months
for the disease to evolve from acute myocardial infarction,
cutaneous lesions and exacerbation of asthma to peripheral
neuropathy.
Reports show that 45% of the relapses occurred during the
ﬁrst year of therapy, and it occur either very soon or long after
the clinical remission.16 So far, there was no relapse after 8
years of follow up.
Conclusions
EGPA is a multisystem disease, and to obtain the diagnosis can
be challenging. High suspicion for EGPA should be raised espe-
cially in young patients who presented with acute coronary
syndrome without any risk factors associated with history of
asthma and peripheral eosinophilia of more  than 10%.
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